NTRA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

576.72M

+21.14%

-0.490

+19.45%

609.88M

+21.53%

-0.497

-0.68%

632.35M

+15.69%

-0.492

-33.54%

Estimates Revision

The market is revising Upward the revenue expectations for Natera, Inc. (NTRA) for FY2025, with the revenue forecasts being adjusted by 7.54% over the past three months. During the same period, the stock price has changed by 38.42%.

Revenue Estimates for FY2025

Revise Upward

+7.54%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+21.9%

In Past 3 Month

Stock Price

Go Up

+38.42%

In Past 3 Month

15 Analyst Rating

Wall Street analysts forecast NTRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRA is 233.50 USD with a low forecast of 172.00 USD and a high forecast of 280.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

172.00

Averages

233.50

High

280.00

Current: 0.000

Low

172.00

Averages

233.50

High

280.00

TD Cowen

Buy

maintain

$240 -> $280

2026-01-07

New

Reason

TD Cowen

Price Target

$240 -> $280

2026-01-07

New

maintain

Buy

Reason

TD Cowen raised the firm's price target on Natera to $280 from $240 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics group as part of a Q4 preview. It expects solid results and 2026 outlooks for the sector, saying strong fundamentals remain.

Citi

NULL -> Buy

initiated

$300

2026-01-07

New

Reason

Citi

Price Target

$300

2026-01-07

New

initiated

NULL -> Buy

Reason

Citi initiated coverage of Natera with a Buy rating and $300 price target. The company is an "established player" in the women's and organ health markets, but its "dominant position" in the growing molecular residual disease market is the focus for investors, the analyst tells investors in a research note. Citi believes the shares warrant a premium multiple with a "significant" growth runway ahead for Natera.

Guggenheim

Buy

maintain

$230 -> $270

2026-01-05

New

Reason

Guggenheim

Price Target

$230 -> $270

2026-01-05

New

maintain

Buy

Reason

Guggenheim raised the firm's price target on Natera to $270 from $230 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for its covered Diagnostics and Life Sciences Tools companies to reflect recent updates from the companies after meetings with management teams.

Canaccord

Buy

maintain

$260 -> $285

2025-12-22

Reason

Canaccord

Price Target

$260 -> $285

2025-12-22

maintain

Buy

Reason

Canaccord raised the firm's price target on Natera to $285 from $260 and keeps a Buy rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026. Among their covered companies, they maintain the highest level of conviction in the risk-reward profile and share price appreciation potential for Natera.

JPMorgan

NULL

Overweight

maintain

$250 -> $260

2025-12-15

Reason

JPMorgan

Price Target

$250 -> $260

2025-12-15

maintain

NULL

Overweight

Reason

JPMorgan raised the firm's price target on Natera to $260 from $250 and keeps an Overweight rating on the shares. The firm updated models in the life science tools and diagnostics group.

Barclays

NULL -> Overweight

maintain

$230 -> $270

2025-12-15

Reason

Barclays

Price Target

$230 -> $270

2025-12-15

maintain

NULL -> Overweight

Reason

Barclays raised the firm's price target on Natera to $270 from $230 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Natera Inc (NTRA.O) is -110.29, compared to its 5-year average forward P/E of -39.49. For a more detailed relative valuation and DCF analysis to assess Natera Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-39.49

Current PE

-110.29

Overvalued PE

-4.32

Undervalued PE

-74.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-41.16

Current EV/EBITDA

-111.29

Overvalued EV/EBITDA

-3.17

Undervalued EV/EBITDA

-79.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

8.93

Current PS

12.75

Overvalued PS

12.89

Undervalued PS

4.97

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 265.72% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NTRA News & Events

Events Timeline

No data

News

8.0

01-09Barron's

Clinical Labs Aim to Prevent Upcoming Medicare Reductions

2.0

01-08NASDAQ.COM

Exelixis Collaborates with Natera for STELLAR-316 CRC Study

6.0

01-07CNBC

UBS Raises Micron Technology Price Target to $400 Following Bullish Investor Meetings

People Also Watch

Frequently Asked Questions

What is Natera Inc (NTRA) stock price today?

The current price of NTRA is 234.31 USD — it has decreased -2.19 % in the last trading day.

What is Natera Inc (NTRA)'s business?

Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.

What is the price predicton of NTRA Stock?

What is Natera Inc (NTRA)'s revenue for the last quarter?

Natera Inc revenue for the last quarter amounts to 592.18M USD, increased 34.66 % YoY.

What is Natera Inc (NTRA)'s earnings per share (EPS) for the last quarter?

Natera Inc. EPS for the last quarter amounts to -0.64 USD, increased 146.15 % YoY.

What changes have occurred in the market's expectations for Natera Inc (NTRA)'s fundamentals?

How many employees does Natera Inc (NTRA). have?

Natera Inc (NTRA) has 4424 emplpoyees as of January 10 2026.

What is Natera Inc (NTRA) market cap?

Today NTRA has the market capitalization of 32.67B USD.